Sickle Cell Crisis in Adults

Critical Alerts

⚠️ Red Flag: Life-Threatening Emergencies in Sickle Cell Disease:

• Acute Chest Syndrome (ACS): New pulmonary infiltrate + respiratory symptoms - leading cause of death in adults with SCD [1]
• Fever > 38.5C: Functional asplenia creates risk of overwhelming sepsis - mortality up to 50% if untreated [2]
• Acute Neurological Deficit: Stroke occurs in 11% by age 20 - requires emergent exchange transfusion [3]
• Rapidly Falling Hemoglobin: Consider splenic sequestration (especially HbSC) or aplastic crisis
• Multi-Organ Failure: Indicates severe crisis requiring ICU and exchange transfusion
• Priapism > 4 hours: Ischemic emergency requiring aspiration and phenylephrine injection

---

Overview

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a point mutation in the beta-globin gene (HBB) resulting in substitution of valine for glutamic acid at position 6, producing abnormal hemoglobin S (HbS). [4] Under conditions of deoxygenation, acidosis, or dehydration, HbS polymerizes, causing red blood cells to assume a rigid, sickled morphology. These deformed cells cause vaso-occlusion of the microvasculature, leading to tissue ischemia, inflammation, and progressive multi-organ damage. [5]

Sickle cell crisis refers to acute clinical events requiring emergency evaluation and treatment. The most common presentation is the vaso-occlusive crisis (VOC), characterized by severe pain. However, life-threatening crises including acute chest syndrome, stroke, and sepsis require immediate recognition and aggressive intervention. SCD is the most common inherited hemoglobinopathy worldwide, with approximately 300,000 affected births annually, predominantly in sub-Saharan Africa, India, and the Mediterranean region. [6]

Modern comprehensive care, including newborn screening, pneumococcal prophylaxis, hydroxyurea, and chronic transfusion programs, has dramatically improved life expectancy from a median of 14 years in the 1970s to over 50 years in high-income settings. [7] Despite these advances, SCD remains associated with significant morbidity and early mortality, with acute complications representing the leading cause of emergency department visits and hospitalizations.

---

Epidemiology

Global and Regional Burden

Geographic Distribution

Sickle cell trait (HbAS) is maintained at high frequency in regions endemic for Plasmodium falciparum malaria due to heterozygote advantage, conferring ~90% protection against severe malaria. [12] The sickle gene is most prevalent in:

• Sub-Saharan Africa: HbS allele frequency 5-20%
• Arabian Peninsula and India: 5-25% in tribal populations
• Mediterranean Basin: Greece, Turkey, southern Italy
• Americas: Descendants of African and Mediterranean populations

Genotype-Phenotype Correlations

---

Aetiology and Pathophysiology

Molecular Basis of Sickling

The HbS mutation (GAG to GTG at codon 6) substitutes hydrophobic valine for hydrophilic glutamic acid on the beta-globin surface. [4] In the deoxygenated state, this valine residue interacts with a complementary hydrophobic pocket on adjacent hemoglobin molecules, initiating polymer formation.

Polymerization Cascade:

1. Nucleation phase: Initial HbS tetramers aggregate (rate-limiting step)
2. Elongation phase: Rapid polymer fiber extension
3. Fiber alignment: Multiple fibers form parallel bundles
4. Cell deformation: Polymer bundles distort the erythrocyte membrane
5. Irreversible sickling: Repeated cycles damage the membrane permanently

Exam Detail: Factors Affecting Polymerization Rate:

• Intracellular HbS concentration: Polymerization occurs above a threshold (delay time inversely proportional to [HbS]^30)
• Oxygen saturation: Deoxy-HbS polymerizes; oxy-HbS does not
• pH: Acidosis shifts oxygen dissociation curve right, promoting deoxygenation
• HbF concentration: HbF cannot co-polymerize with HbS, reducing sickling
• Temperature: Polymerization increases with higher temperature
• 2,3-DPG levels: Elevated levels promote deoxygenation

Triggers for Acute Crisis

Pathophysiology of Vaso-Occlusion

Vaso-occlusion is a complex, multifactorial process involving sickled erythrocytes, activated endothelium, leukocytes, and platelets: [13]

1. Endothelial activation: Chronic hemolysis releases free hemoglobin, scavenging nitric oxide (NO) and causing endothelial dysfunction
2. Adhesion molecule expression: Upregulation of VCAM-1, ICAM-1, E-selectin, P-selectin on endothelium
3. Erythrocyte adhesion: Sickled cells express phosphatidylserine and adhere to activated endothelium
4. Leukocyte recruitment: Activated neutrophils and monocytes propagate vaso-occlusion
5. Platelet activation: Thrombin generation and microthrombi formation
6. Ischemia-reperfusion injury: Intermittent vaso-occlusion causes oxidative stress and inflammation

Hemolysis and Vasculopathy

Chronic intravascular hemolysis releases cell-free hemoglobin and arginase, depleting NO and L-arginine: [14]

• Reduced NO bioavailability: Impaired vasodilation, platelet activation
• Pulmonary hypertension: Present in 30% of adults; tricuspid regurgitant velocity > 2.5 m/s
• Leg ulcers: NO deficiency impairs wound healing
• Priapism: Impaired smooth muscle relaxation
• Stroke: Endothelial dysfunction and large vessel vasculopathy

---

Types of Sickle Cell Crises

1. Vaso-Occlusive Crisis (Painful Crisis)

Definition: Acute episode of severe pain caused by microvascular occlusion, representing the hallmark manifestation of SCD and the most common reason for emergency presentation.

Epidemiology:

• Accounts for > 90% of SCD-related hospital admissions [15]
• Median 0.8 episodes per patient-year in HbSS (highly variable: 0-10+ per year)
• Mean duration: 4-7 days
• Associated with increased mortality if frequent (> 3 episodes/year)

Pathophysiology:

• Microvascular occlusion in bone marrow, muscle, viscera
• Tissue ischemia and inflammation
• Pain mediated by prostaglandins, substance P, inflammatory cytokines
• Bone marrow infarction with cortical bone necrosis

Clinical Presentation:

• Location: Long bones (femur, tibia, humerus), spine, ribs, pelvis, sternum
• Character: Deep, boring, throbbing pain
• Onset: Typically acute over hours, often with identifiable trigger
• Pattern: Often similar to prior crises for individual patients
• Associated features: Low-grade fever (less than 38.5C), malaise, joint swelling

Examination Findings:

• Tenderness over affected areas (often diffuse)
• May have warmth and swelling
• Dactylitis (hand-foot syndrome) in young children
• No specific objective findings (diagnosis is clinical)

2. Acute Chest Syndrome (ACS)

Definition: New pulmonary infiltrate involving at least one complete lung segment on chest imaging, accompanied by one or more of: fever > 38.5C, respiratory symptoms (cough, dyspnea, tachypnea, chest pain), or hypoxia. [1]

Epidemiology:

• Incidence: 12.8 episodes per 100 patient-years in HbSS [16]
• Leading cause of death in adults with SCD (accounting for 25% of deaths)
• 50% develop during hospitalization for VOC
• Mortality rate: 4-9% per episode; up to 20% with mechanical ventilation

Aetiology (often multifactorial):

Pathophysiology:

1. Hypoventilation from chest wall pain leads to atelectasis
2. V/Q mismatch causes regional hypoxemia
3. Local sickling and vaso-occlusion in pulmonary vasculature
4. Fat embolism from bone marrow necrosis (phospholipase release causes ARDS pattern)
5. Infection propagates inflammation and further sickling
6. Positive feedback loop leading to respiratory failure

Clinical Pearl: ACS Progression Pattern: Up to 50% of ACS cases evolve from initially admitted VOC. Any patient hospitalized for VOC who develops fever, chest pain, increasing oxygen requirement, or cough should have repeat chest imaging regardless of initial CXR findings. Serial monitoring with incentive spirometry every 2 hours while awake is critical for prevention.

3. Stroke and Cerebrovascular Disease

Epidemiology:

• Stroke incidence: 11% by age 20 in untreated HbSS [3]
• TCD screening and chronic transfusion reduces stroke risk by 92%
• Silent cerebral infarcts: Present in 37% of children by age 14 [17]
• Hemorrhagic stroke more common in adults (adults:children ratio 2:1)

Types of Cerebrovascular Events:

Pathophysiology of SCD Vasculopathy:

• Chronic endothelial injury from hemolysis and sickling
• Intimal hyperplasia and progressive stenosis of large cerebral arteries
• Moyamoya-pattern collateral vessel formation
• Fragile collaterals prone to rupture (hemorrhagic stroke risk)

Transcranial Doppler (TCD) Screening:

• Identifies children at high stroke risk
• Annual screening recommended ages 2-16 years
• High-risk threshold: Time-averaged mean velocity (TAMV) > 200 cm/s in MCA or ICA
• Conditional risk: TAMV 170-199 cm/s (repeat in 3-6 months)
• Chronic transfusion reduces stroke in high-risk patients by 92% [3]

4. Aplastic Crisis

Definition: Transient arrest of erythropoiesis causing acute worsening of anemia, characterized by absent reticulocytosis.

Aetiology:

• Almost exclusively caused by Parvovirus B19 infection
• Tropism for erythroid progenitors (P antigen receptor)
• Halts RBC production for 7-10 days

Clinical Features:

• Acute severe anemia (Hgb may fall to 2-3 g/dL)
• Inappropriately low or absent reticulocyte count (less than 1%)
• Fatigue, pallor, dyspnea, high-output cardiac failure
• Often family clusters (siblings affected within days)

Key Points:

• Self-limited (recovery within 10-14 days)
• Single episode confers lifelong immunity
• Contagious to non-immune contacts
• Particular danger to pregnant women (hydrops fetalis risk)

5. Splenic Sequestration Crisis

Definition: Acute pooling of blood within the spleen causing rapid splenic enlargement, hypovolemia, and potentially fatal circulatory collapse.

Epidemiology:

• More common in children less than 5 years (before autosplenectomy)
• Can occur in adults with HbSC or HbS-beta+ thalassemia (preserved splenic function)
• Recurrence rate: 50% after first episode
• Mortality: 10-15% if untreated

Clinical Features:

• Sudden onset of pallor, fatigue, abdominal distension
• Rapidly enlarging spleen (may increase > 2 cm from baseline)
• Hemoglobin drop ≥2 g/dL from baseline
• Reticulocytosis (marrow is active, unlike aplastic crisis)
• Hypovolemic shock if severe

Management Principles:

• Aggressive fluid resuscitation
• Urgent RBC transfusion (transfuse cautiously; autotransfusion from spleen as it shrinks can cause hyperviscosity)
• Consider splenectomy after stabilization if recurrent

6. Hemolytic Crisis

Definition: Acute acceleration of hemolysis beyond the chronic baseline, causing rapid worsening of anemia.

Causes:

• Delayed hemolytic transfusion reaction (DHTR) - most dangerous
• Co-existent G6PD deficiency with oxidative stress
• Infection (malaria in endemic regions)
• Drug-induced hemolysis

⚠️ Red Flag: Delayed Hemolytic Transfusion Reaction (DHTR):

• Occurs 5-20 days post-transfusion
• Destruction of both transfused AND autologous RBCs (hyperhemolysis)
• Hemoglobin may fall BELOW pre-transfusion level
• Pain crisis, dark urine, fever, falling hemoglobin
• Avoid further transfusion unless life-threatening anemia
• Treat with IVIG, high-dose steroids, erythropoietin

7. Priapism

Definition: Prolonged, painful penile erection unrelated to sexual stimulation, caused by vaso-occlusion of the corpora cavernosa.

Classification:

Epidemiology:

• Lifetime incidence: 35-42% of males with SCD
• Mean age of first episode: 12-15 years
• Risk of erectile dysfunction: 30-90% with ischemic priapism > 24 hours

---

Red Flags and Emergency Recognition

Immediate Life Threats

Warning Signs During Admission

• Escalating oxygen requirement
• Development of chest pain or cough during VOC admission
• Worsening pain despite adequate analgesia
• Altered mental status
• New abdominal distension
• Rapidly falling hemoglobin

---

Clinical Presentation

History Taking Framework

Essential Elements:

Physical Examination

Systematic Approach:

---

Differential Diagnosis

Pain Crisis Mimics

Acute Chest Syndrome vs. Similar Presentations

---

Investigations

Initial Laboratory Panel

Additional Studies Based on Presentation

HbS Quantification

• Hemoglobin electrophoresis or HPLC: Quantifies HbS, HbA (if transfused), HbF
• Pre-transfusion HbS typically 80-95% in untransfused HbSS
• Target HbS less than 30% for acute stroke, severe ACS, multi-organ failure

Transfusion Considerations

Clinical Pearl: Extended Phenotype Matching: SCD patients have high rates of RBC alloimmunization (up to 30%) due to antigen differences between donors (predominantly Caucasian) and recipients (predominantly African ancestry). [18] All transfusions should be matched for:

• ABO, Rh (D, C, E, c, e)
• Kell (K)
• Additional extended matching (Duffy, Kidd, MNS) if antibodies detected

---

Management

Principles of Emergency Care

1. Rapid assessment: ABC, vital signs, oxygen saturation
2. Aggressive pain control: Opioids within 30 minutes of arrival
3. Identify triggers: Especially infection
4. Hydration: Avoid both dehydration and fluid overload
5. Recognize complications: ACS, stroke, multi-organ failure
6. Transfusion when indicated: Simple or exchange transfusion

Vaso-Occlusive Crisis Management

Analgesia Protocol

Key Analgesia Principles: [19]

• Titrate to patient's reported pain level (target ≥50% reduction)
• Use patient's known effective regimen from prior admissions
• PCA is often more effective than PRN dosing for severe pain
• Time to first analgesia should be less than 30 minutes from arrival
• Avoid meperidine (normeperidine accumulation causes seizures)

Supportive Care

Acute Chest Syndrome Management

Severity Assessment

Treatment Protocol

Exchange Transfusion Indications [21]

Absolute Indications:

• Acute stroke
• Severe ACS (PaO2 less than 60 mmHg on supplemental O2, or rapid deterioration)
• Multi-organ failure
• Hepatic sequestration
• Preoperative for high-risk surgery (neurosurgery, cardiac surgery)

Relative Indications:

• Refractory priapism
• Recurrent ACS despite simple transfusion
• Severe, refractory VOC
• Pregnancy with severe complications

Exchange Transfusion Targets:

• Target HbS: less than 30% (acute stroke, severe ACS) or less than 50% (other indications)
• Target Hgb: ~10 g/dL (not higher to avoid hyperviscosity)
• Method: Automated erythrocytapheresis preferred; manual exchange if unavailable

Stroke Management

Exam Detail: Secondary Stroke Prevention:

• Chronic transfusion therapy indefinitely (target HbS less than 30%)
• If unable to continue transfusion: Hydroxyurea + phlebotomy transition (SWiTCH trial showed inferior stroke prevention) [22]
• Revascularization surgery (encephaloduroarteriosynangiosis) considered for progressive moyamoya

Fever and Sepsis Protocol

All febrile SCD patients (> 38.5C) require: [2]

1. Immediate blood cultures (before antibiotics if possible)
2. Empiric antibiotics within 1 hour: Ceftriaxone 2g IV
3. Consider additional coverage: Vancomycin if central line or skin infection suspected
4. Workup: CBC, CXR, urinalysis, consider lumbar puncture if meningitis suspected
5. Low threshold for admission: Especially if ill-appearing, persistent fever, or inadequate follow-up

Common Pathogens:

• Streptococcus pneumoniae (most common, most lethal)
• Haemophilus influenzae
• Salmonella species (osteomyelitis, bacteremia)
• Staphylococcus aureus

Priapism Emergency Management

Time-Critical: Ischemic damage begins at 4-6 hours; erectile dysfunction rate increases with delay.

---

Chronic Complications

Overview of End-Organ Damage

Pulmonary Hypertension

Epidemiology and Significance:

• Echocardiographic evidence (TRV > 2.5 m/s) in 30% of adults [23]
• Right heart catheterization-confirmed PH in 6-10%
• Major predictor of mortality (HR 10.1 for TRV > 3.0 m/s)

Pathophysiology:

• Chronic hemolysis depletes NO, causing vasoconstriction
• In situ thrombosis
• Hypoxia-driven remodeling
• Chronic high cardiac output

Screening:

• Annual echocardiogram recommended for adults
• TRV > 2.5 m/s warrants further evaluation
• Right heart catheterization for definitive diagnosis

Management:

• Optimize SCD treatment (hydroxyurea, transfusions)
• Treat contributing factors (sleep apnea, thromboembolic disease)
• PH-specific therapy (sildenafil, endothelin receptor antagonists) controversial; limited evidence

Sickle Cell Nephropathy

Spectrum of Renal Disease:

Management:

• ACE inhibitors/ARBs for proteinuria
• Avoid nephrotoxins (NSAIDs, contrast)
• Hydroxyurea may slow progression
• Standard CKD management for advanced disease

Avascular Necrosis (Osteonecrosis)

Epidemiology:

• Femoral head involvement in 10-50% of adults with SCD
• Humeral head in 5-12%
• Mean age of onset: 25-35 years

Pathophysiology:

• Bone marrow infarction disrupts blood supply to subchondral bone
• Trabecular collapse and joint destruction

Staging (Ficat Classification):

---

Disease-Modifying Therapies

Hydroxyurea

Mechanism of Action:

• Increases HbF production (HbF inhibits HbS polymerization)
• Reduces WBC count and adhesion
• Increases NO production
• Reduces reticulocyte and platelet counts

Evidence Base:

• MSH trial: 44% reduction in VOC, 39% reduction in ACS, reduced hospitalizations [24]
• Reduces mortality by 40% in adults
• FDA-approved for adults and children (> 2 years)

Dosing:

Contraindications:

• Pregnancy (teratogenic)
• Severe renal impairment (dose adjustment required)
• Severe hepatic impairment

Chronic Transfusion Therapy

Indications:

• Primary stroke prevention (abnormal TCD)
• Secondary stroke prevention
• Recurrent ACS or severe VOC despite hydroxyurea
• Pregnancy with severe complications
• Pre-operative preparation for major surgery

Target:

• Maintain HbS less than 30% (stroke prevention) or less than 50% (other indications)
• Transfusion every 3-4 weeks

Complications:

• Iron overload (chelation required: deferoxamine, deferasirox, or deferiprone)
• Alloimmunization
• Transfusion reactions

Newer Disease-Modifying Agents

---

Special Populations

Pregnancy

Risks:

• Increased frequency of VOC (especially third trimester)
• Higher rates of preeclampsia, preterm labor, IUGR
• Maternal mortality 1-2% in developed countries
• Fetal mortality 15-20% in severe cases

Management Principles:

• Discontinue hydroxyurea pre-conception (teratogenic)
• Continue folic acid supplementation
• Low threshold for hospitalization during crises
• Prophylactic transfusion controversial; consider for severe disease
• Multidisciplinary care (hematology, MFM, anesthesia)
• Regional anesthesia preferred for delivery

Surgical Patients

Preoperative Optimization:

• Aim for Hgb ~10 g/dL (simple transfusion usually sufficient)
• Exchange transfusion for high-risk surgery (HbS less than 30%)
• Aggressive hydration perioperatively
• Maintain normothermia
• Adequate oxygenation
• Effective pain management postoperatively

Evidence:

• TAPS trial showed simple transfusion (Hgb 10) non-inferior to aggressive exchange for moderate-risk surgery

Sickle Cell Trait (HbAS)

Generally benign, but associated rare complications include:

• Splenic infarction at altitude (> 5,000 feet)
• Exertional rhabdomyolysis (military training, athletes)
• Hyposthenuria and hematuria
• Venous thromboembolism (slightly increased risk)
• Medullary renal carcinoma (rare but associated)

Important: Do NOT treat trait patients like SCD patients.

---

Prognosis and Prevention

Prognostic Factors

Prevention of Complications

Primary Prevention:

• Pneumococcal vaccination (PCV13 and PPSV23)
• Meningococcal vaccination (conjugate and serogroup B)
• Haemophilus influenzae type b (Hib) vaccination
• Annual influenza vaccination
• Penicillin prophylaxis until age 5
• Folic acid supplementation
• Hydroxyurea (reduces VOC, ACS, transfusions, mortality)

Screening Programs:

• Annual TCD (ages 2-16) for stroke prevention
• Annual ophthalmologic exam for retinopathy
• Annual echocardiogram for pulmonary hypertension
• Renal function monitoring (proteinuria screening)

---

Disposition

ICU Admission Criteria

• Severe ACS (high O2 requirement, mechanical ventilation)
• Acute stroke
• Multi-organ failure
• Hemodynamic instability (sepsis, sequestration)
• Exchange transfusion in progress

Ward Admission Criteria

• VOC requiring parenteral opioids
• Mild-moderate ACS
• Fever requiring IV antibiotics
• Aplastic crisis requiring transfusion
• Moderate splenic sequestration (stable)

Discharge Criteria

• Pain controlled on oral analgesics
• Afebrile > 24 hours
• SpO2 > 95% on room air
• Tolerating oral hydration
• Close follow-up arranged (hematology within 1-2 weeks)

---

Common Exam Questions

Viva Questions and Model Answers

Q1: A 25-year-old with SCD presents with severe bone pain and low-grade fever. How do you approach this patient?

"This presentation suggests a vaso-occlusive crisis, but I would systematically rule out serious complications and mimics.

My immediate priorities are:

1. Assessment: ABC, vital signs, pain score, oxygen saturation
2. Analgesia: IV opioids within 30 minutes - typically morphine 0.1 mg/kg IV
3. Investigations: CBC comparing to baseline, reticulocyte count, renal function, LDH, blood cultures if temperature > 38.5C, chest X-ray if any respiratory symptoms
4. Supportive care: IV fluids at 1-1.5x maintenance, incentive spirometry every 2 hours

I would specifically assess for:

• Acute chest syndrome (respiratory symptoms, infiltrate)
• Infection/sepsis (functional asplenia)
• Osteomyelitis (focal signs, persistent fever)

Red flags requiring escalation include fever > 38.5C, new pulmonary infiltrate, or any neurological symptoms."

Q2: What are the indications for exchange transfusion in SCD?

"Exchange transfusion is indicated when rapid reduction of HbS is required. The main indications are:

Absolute indications:

• Acute stroke - target HbS less than 30%
• Severe acute chest syndrome - defined as PaO2 less than 60 mmHg on supplemental oxygen or rapid deterioration
• Multi-organ failure
• Hepatic sequestration

Relative indications:

• Refractory priapism
• Severe, refractory vaso-occlusive crisis
• Preoperative for high-risk surgery
• Pregnancy with severe complications

The target for exchange is HbS less than 30% for stroke and severe ACS, or less than 50% for other indications, with a target hemoglobin of approximately 10 g/dL to avoid hyperviscosity."

Q3: How do you differentiate osteomyelitis from bone infarction in SCD?

"This is a common diagnostic challenge. Key differentiating features include:

MRI is the most sensitive imaging modality. In osteomyelitis, there is cortical destruction, periosteal reaction, and soft tissue abscess. Bone scan is less helpful as both conditions cause increased uptake.

If in doubt, I would treat empirically for both while awaiting MRI, using antibiotics covering Salmonella and Staphylococcus (e.g., ceftriaxone + flucloxacillin or vancomycin)."

Common Mistakes to Avoid

• Missing ACS evolution in a patient admitted for VOC
• Undertreating pain due to concern about opioid dependence
• Transfusing to Hgb > 10 g/dL (causes hyperviscosity)
• Using meperidine (normeperidine causes seizures)
• Giving supplemental O2 to non-hypoxic patients
• Forgetting incentive spirometry for ACS prevention
• Not using extended phenotype-matched blood
• Delaying antibiotics for febrile patients

---

Quality Metrics and Performance Standards

Emergency Department Metrics

Inpatient Quality Indicators

Documentation Requirements

Essential Documentation:

• Baseline hemoglobin (from patient or prior records)
• Prior complication history (ACS, stroke, transfusions)
• Current disease-modifying therapy (hydroxyurea adherence)
• Pain score and treatment response at regular intervals
• Transfusion history and known alloantibodies
• HbS percentage if available
• Immunization status (pneumococcal, meningococcal)

---

Patient Education

Understanding Sickle Cell Disease

Key Messages for Patients:

• "Sickle cell disease causes your red blood cells to become stiff and crescent-shaped under certain conditions, which can block blood vessels and cause pain"
• "This is a lifelong condition that requires ongoing management and monitoring"
• "Taking your medications as prescribed (especially hydroxyurea) can significantly reduce crises"
• "Staying hydrated, avoiding extreme temperatures, and managing stress help prevent crises"

Recognizing Emergencies

When to Seek Immediate Medical Care:

Lifestyle Modifications

Prevention Strategies:

Medication Adherence

Hydroxyurea Education:

• "This medication increases the protective hemoglobin (HbF) in your blood"
• "It takes 3-6 months to see full benefit"
• "Regular blood tests are needed to monitor for side effects"
• "Do not become pregnant while taking this medication - it can cause birth defects"
• "Missing doses reduces effectiveness - use reminders or pill organizers"

Vaccinations

Required Immunizations:

• Pneumococcal: PCV13 and PPSV23 (with boosters)
• Meningococcal: Conjugate (MenACWY) and Serogroup B
• Haemophilus influenzae type b (Hib)
• Annual influenza vaccine
• COVID-19 vaccination and boosters
• Hepatitis B (if not immune)

---

Clinical Algorithms

Emergency Department Assessment Algorithm

Patient with SCD presents to ED
            |
            v
    Initial Assessment
    - ABCs, vital signs
    - SpO2 on room air
    - Pain score (0-10)
            |
    +-----------+------------+
    |           |            |
    v           v            v
Fever > 38.5C  Respiratory   Neurological
              symptoms      symptoms
    |           |            |
    v           v            v
Blood cultures  CXR         Emergent
Ceftriaxone 2g  ABG if      CT/MRI Head
STAT           hypoxic      Exchange
                            transfusion if
    |           |           stroke confirmed
    v           v
Normal CXR:   New infiltrate:
Continue VOC  Diagnose ACS
management    - O2 therapy
              - Antibiotics
              - Transfusion decision

ACS Severity and Transfusion Decision Algorithm

Acute Chest Syndrome Diagnosed
(New infiltrate + respiratory symptoms)
            |
            v
    Assess Severity
            |
    +-------+-------+-------+
    |               |               |
    v               v               v
  MILD          MODERATE         SEVERE
SpO2 > 92% RA   SpO2 88-92%     SpO2 less than 88%
Single lobe    Multi-lobar     PaO2 less than 60 mmHg
Stable         OR worsening    Rapid deterioration
                               OR mechanical vent
    |               |               |
    v               v               v
Simple          Simple          EXCHANGE
transfusion     transfusion     TRANSFUSION
(Hgb to 10)     + ICU consult   + ICU admission
Ward admission  Close monitoring Target HbS less than 30%

Pain Crisis Management Protocol

Time 0: Patient Arrival
    |
    v
T+15 min: Triage + Initial Assessment
    - Pain score
    - Vital signs
    - Brief focused history
    |
    v
T+30 min: ANALGESIA ADMINISTERED
    - Morphine 0.1 mg/kg IV OR
    - Hydromorphone 0.015 mg/kg IV
    |
    v
T+45 min: Reassess Pain Score
    |
    +-------+-------+
    |               |
    v               v
Pain reduced    Pain unchanged
by ≥50%         or worsening
    |               |
    v               v
Continue        Re-dose opioid
current regimen (q15-20 min)
+ supportive    Consider PCA
care            Consider adjuncts

---

Advanced Clinical Considerations

Transfusion Medicine in SCD

Alloimmunization Management

Risk Factors for Alloimmunization:

• Multiple transfusions
• Antigen mismatch between donor (Caucasian) and recipient (African ancestry)
• Inflammatory state during transfusion
• History of prior antibodies

Prevention Strategies:

• Extended phenotype matching (Rh C, c, E, e; Kell K)
• Leukoreduction
• Consider Duffy, Kidd, MNS matching if prior antibodies
• Maintain transfusion records across healthcare systems

Management of Alloimmunized Patients:

• Comprehensive antibody identification
• Antigen-negative unit procurement
• Longer crossmatch time - notify blood bank early
• Consider autologous donation programs where feasible

Delayed Hemolytic Transfusion Reaction (DHTR)

Exam Detail: DHTR - Critical Recognition:

DHTR is a life-threatening complication unique to SCD patients, characterized by destruction of both transfused AND autologous RBCs (hyperhemolysis).

Timeline: 5-20 days post-transfusion

Clinical Features:

• Hemoglobin falls BELOW pre-transfusion level
• Pain crisis symptoms (often mistaken for VOC)
• Dark urine (hemoglobinuria)
• Fever, malaise
• Positive DAT or new alloantibody

Mechanism:

• Anamnestic antibody response to transfused cells
• Bystander hemolysis of autologous cells (macrophage activation)
• Reticulocytopenia due to bone marrow suppression

Management:

1. AVOID further transfusion unless life-threatening anemia
2. High-dose corticosteroids (methylprednisolone 250-1000 mg IV)
3. IVIG (0.4 g/kg x 5 days or 1 g/kg x 2 days)
4. Erythropoietin to stimulate red cell production
5. Rituximab in refractory cases
6. Supportive care (oxygen, fluids)

Prevention:

• Extended phenotype matching
• Maintain centralized antibody database
• Limit transfusion to clear indications

Multidisciplinary Care Model

Essential Team Members:

Transition of Care (Pediatric to Adult)

Key Transition Elements:

• Begin transition planning at age 12-14
• Structured transition program (ages 16-18)
• Warm handoff to adult hematology team
• Medication reconciliation and adherence assessment
• Insurance continuity planning
• Identification of adult emergency care preferences
• Education on self-advocacy

End-of-Life Considerations

Palliative Care Integration:

• Early palliative care referral for refractory symptoms
• Advance care planning discussions
• Pain management optimization
• Goals of care conversations for progressive organ failure
• Hospice eligibility for end-stage complications

---

Research and Emerging Therapies

Gene Therapy

Current Approaches:

Outcomes:

• Elimination or near-elimination of VOC in majority of patients
• HbF levels of 40-50% achieved
• Potential cure, though long-term safety data emerging

Limitations:

• Myeloablative conditioning required
• High cost ($2+ million)
• Limited access globally
• Long-term malignancy surveillance needed

Novel Pharmacotherapies

Curative Approaches

Hematopoietic Stem Cell Transplantation:

• Curative potential with matched sibling donor
• Overall survival ~95% in pediatric patients
• Limited by donor availability (15-20% have matched sibling)
• Haploidentical and unrelated donor protocols expanding
• Gene therapy may overcome donor limitation

---

Key Clinical Pearls

Diagnostic Pearls

• Pain crisis is a clinical diagnosis - no objective test; compare to patient's prior pattern
• ACS may evolve from VOC - repeat CXR if any new respiratory symptoms
• Fever > 38.5C is a medical emergency due to functional asplenia
• Low reticulocytes + falling Hgb = aplastic crisis (not hemolytic)
• Any neurological change warrants emergent imaging

Treatment Pearls

• Target time to first analgesia: less than 30 minutes
• Transfuse to Hgb 10, not higher (hyperviscosity)
• Exchange transfusion targets HbS less than 30% for stroke/severe ACS
• Incentive spirometry q2h prevents ACS (most effective intervention)
• Cover atypical organisms in ACS (azithromycin/fluoroquinolone)

Disposition Pearls

• Most VOC patients require admission
• Low threshold for ICU with ACS - rapid deterioration common
• Stroke requires immediate exchange transfusion - do not delay
• Arrange hematology follow-up before discharge

---

References

1. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865. doi:10.1056/NEJM200006223422502

2. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14(1):e2-e12. doi:10.1016/j.ijid.2009.03.010

3. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11. doi:10.1056/NEJM199807023390102

4. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178(4537):792-794. doi:10.1038/178792a0

5. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031. doi:10.1016/S0140-6736(10)61029-X

6. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561-1573. doi:10.1056/NEJMra1510865

7. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530-535. doi:10.1002/ajh.23683

8. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512-S521. doi:10.1016/j.amepre.2010.01.022

9. Centers for Disease Control and Prevention. Data & statistics on sickle cell disease. Accessed 2024. https://www.cdc.gov/sickle-cell/data/

10. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-1294. doi:10.1001/jama.2010.378

11. Glassberg JA, Tanabe P, Chow A, et al. Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Ann Emerg Med. 2013;62(4):293-302.e10. doi:10.1016/j.annemergmed.2013.02.004

12. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151. doi:10.1016/S0140-6736(12)61229-X

13. Zhang D, Xu C, Manwani D, Bhalla RC. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809. doi:10.1182/blood-2015-09-618538

14. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. doi:10.1056/NEJMoa035477

15. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656. doi:10.1182/blood-2012-04-383430

16. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood. 1994;84(2):643-649. doi:10.1182/blood.V84.2.643.643

17. Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10):1653-1661. doi:10.1182/blood-2014-09-599852

18. Chou ST, Alsawas M, Engelman A, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355. doi:10.1182/bloodadvances.2019001143

19. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701. doi:10.1182/bloodadvances.2020001851

20. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333(11):699-703. doi:10.1056/NEJM199509143331104

21. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142

22. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932. doi:10.1182/blood-2011-11-392340

23. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44-53. doi:10.1056/NEJMoa1005565

24. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322. doi:10.1056/NEJM199505183322001